Xeris Biopharma Holdings, Inc.
XERS
$8.48
-$0.05-0.59%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -31.10M | 2.23M | 11.08M | 621.00K | -1.93M |
| Total Depreciation and Amortization | 3.21M | 3.21M | 3.20M | 3.19M | 3.16M |
| Total Amortization of Deferred Charges | 907.00K | 889.00K | 866.00K | 843.00K | 820.00K |
| Total Other Non-Cash Items | 41.85M | 4.14M | 5.27M | 7.64M | 5.01M |
| Change in Net Operating Assets | -6.60M | -603.00K | -373.00K | 6.14M | -6.88M |
| Cash from Operations | 8.26M | 9.87M | 20.04M | 18.43M | 182.00K |
| Capital Expenditure | -209.00K | -325.00K | -333.00K | -71.00K | -279.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -209.00K | -325.00K | -333.00K | -71.00K | -279.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.13M | 8.18M | 1.27M | 14.33M | 1.80M |
| Repurchase of Common Stock | -191.00K | -17.02M | -1.54M | -478.00K | -860.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.94M | -8.84M | -266.00K | 13.85M | 942.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.00M | 708.00K | 19.44M | 32.21M | 845.00K |